Syntis Bio Launches with Oral Anti-Obesity Therapy; Akero Initiates Ph3 SYNCHRONY Outcomes Trial in MASH; Merck Initiates H2H Ph3 Oral PCSK9i Trial; Nanexa Doses First Patient in New QM Liraglutide Study
A series of cardiometabolic-related news items have been observed from Syntis Bio, Akero Therapeutics, Merck, and Nanexa AB. Below, FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.